• A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.

    Thumbnail Image

    Files

    O'Connor et al. 2007... Phase I clinical trial.pdf (291.31 KB)

    Date

    2007

    Authors

    Journal Title

    Journal ISSN

    Volume Title

    Publisher

    Access

    openAccess

    Embargo end date

    Citation

    O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J., A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer., Cancer Chemother Pharmacol., 59, 1, 2007, 79 - 87

    Abstract

    Description

    PUBLISHED

    URI

    http://hdl.handle.net/2262/78969

    Collections

    Pharmacy and Pharmaceutical Sciences (Scholarly Publications)
    RSS Feeds

    Endorsement

    Review

    Supplemented By

    Referenced By

    Keywords

    Author's Homepage: http://people.tcd.ie/lodrisc

    Author: O'DRISCOLL, LORRAINE

    Type of material: Journal Article